Edition:
United Kingdom

MEI Pharma Inc (MEIP.OQ)

MEIP.OQ on NASDAQ Stock Exchange Capital Market

2.19USD
16 Feb 2018
Change (% chg)

$0.04 (+1.86%)
Prev Close
$2.15
Open
$2.18
Day's High
$2.21
Day's Low
$2.18
Volume
6,033
Avg. Vol
33,595
52-wk High
$3.26
52-wk Low
$1.49

Chart for

About

MEI Pharma, Inc. is an oncology company. The Company is focused on the clinical development of drugs and therapies for treatment of cancer. The Company's portfolio of clinical drug candidates includes Pracinostat, ME-344 and PWT143. Pracinostat is an orally available histone deacetylase (HDAC) inhibitor indicated for the... (more)

Overall

Beta: 1.43
Market Cap(Mil.): $94.93
Shares Outstanding(Mil.): 36.94
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.64
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-MEI Pharma Says Interim Data Review Supports Continuation Of ME-344 Clinical Study

* MEI PHARMA INTERIM DATA REVIEW SUPPORTS CONTINUATION OF CLINICAL STUDY EVALUATING ME-344 IN PATIENTS WITH BREAST CANCER

13 Feb 2018

BRIEF-MEI Pharma Q2 Loss Per Share $0.16

* ‍AS OF DECEMBER 31, 2017, HAD $42.4 MILLION IN CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS, WITH NO OUTSTANDING DEBT​

08 Feb 2018

BRIEF-Helsinn Group and MEI Pharma's Pracinostat receives orphan drug designation from European Medicines Agency

* HELSINN GROUP AND MEI PHARMA ANNOUNCE THAT PRACINOSTAT HAS RECEIVED ORPHAN DRUG DESIGNATION FROM THE EUROPEAN MEDICINES AGENCY FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) Source text for Eikon: Further company coverage:

11 Jan 2018

BRIEF-MEI Pharma Announces FDA Clearance Of Investigational New Drug Application For CDK Inhibitor Voruciclib

* MEI PHARMA ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR CDK INHIBITOR VORUCICLIB

08 Jan 2018

BRIEF-Mei Pharma enters into at-market equity offering sales agreement

* On Nov. 8, 2017, co entered into at--market equity offering sales agreement with Stifel, Nicolaus & Company, Incorporated, as sales agent​

08 Nov 2017

BRIEF-Mei Pharma announces exclusive license agreement with Presage Biosciences for voruciclib

* Mei Pharma announces exclusive license agreement with Presage Biosciences for voruciclib, an oral, selective cdk inhibitor

05 Sep 2017

Earnings vs. Estimates